SCHEER guidelines rev.1 – Update on the guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devicescovering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties
SCHEER guidelines Rev.1 Update on the guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic,